{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:15:12Z","timestamp":1792271712285,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016253","name":"Atara Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40120-023-00532-2","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T08:02:35Z","timestamp":1694160155000},"page":"1961-1979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8763-9197","authenticated-orcid":false,"given":"Crystal","family":"Watson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3660-5063","authenticated-orcid":false,"given":"Dhanalakshmi","family":"Thirumalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-7647","authenticated-orcid":false,"given":"Arie","family":"Barlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-4796","authenticated-orcid":false,"given":"Eddie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Bogdanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-1520","authenticated-orcid":false,"given":"Kiren","family":"Kresa-Reahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"10","key":"532_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340.","journal-title":"Neurology"},{"issue":"3","key":"532_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/1352458517747407","volume":"25","author":"V Damotte","year":"2019","unstructured":"Damotte V, Lizee A, Tremblay M, et al. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2019;25(3):408\u201318.","journal-title":"Mult Scler"},{"key":"532_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2147\/NDT.S132079","volume":"13","author":"HJ Gross","year":"2017","unstructured":"Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349\u201357.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Pt 12","key":"532_CR4","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1093\/brain\/awt281","volume":"136","author":"T Kalincik","year":"2013","unstructured":"Kalincik T, Vivek V, Jokubaitis V, et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain. 2013;136(Pt 12):3609\u201317.","journal-title":"Brain"},{"issue":"1\u20132","key":"532_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jns.2012.03.017","volume":"318","author":"I Kister","year":"2012","unstructured":"Kister I, Chamot E, Cutter G, et al. Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci. 2012;318(1\u20132):94\u20139.","journal-title":"J Neurol Sci"},{"key":"532_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.msard.2018.09.002","volume":"26","author":"TA Nazareth","year":"2018","unstructured":"Nazareth TA, Rava AR, Polyakov JL, et al. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Mult Scler Relat Disord. 2018;26:219\u201334.","journal-title":"Mult Scler Relat Disord"},{"key":"532_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PPA.S115090","volume":"11","author":"M Tintore","year":"2017","unstructured":"Tintore M, Alexander M, Costello K, et al. The state of multiple sclerosis: current insight into the patient\/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence. 2017;11:33\u201345.","journal-title":"Patient Prefer Adherence"},{"issue":"13","key":"532_CR8","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1177\/1352458519881994","volume":"26","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Claflin SB, Stankovich J, et al. Redefining the multiple sclerosis severity score (MSSS): the effect of sex and onset phenotype. Mult Scler. 2020;26(13):1765\u201374.","journal-title":"Mult Scler"},{"issue":"3","key":"532_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"6","key":"532_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","volume":"4","author":"G Capkun","year":"2015","unstructured":"Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord. 2015;4(6):546\u201354.","journal-title":"Mult Scler Relat Disord"},{"key":"532_CR11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","volume":"9","author":"SB Claflin","year":"2018","unstructured":"Claflin SB, Broadley S, Taylor BV. The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses. Front Neurol. 2018;9:1150.","journal-title":"Front Neurol"},{"issue":"3","key":"532_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","volume":"15","author":"I Kister","year":"2013","unstructured":"Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013;15(3):146\u201358.","journal-title":"Int J MS Care"},{"issue":"12","key":"532_CR13","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.clinthera.2014.08.006","volume":"36","author":"MD Carrithers","year":"2014","unstructured":"Carrithers MD. Update on disease-modifying treatments for multiple sclerosis. Clin Ther. 2014;36(12):1938\u201345.","journal-title":"Clin Ther"},{"issue":"3","key":"532_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/WCO.0000000000000332","volume":"29","author":"BA Cree","year":"2016","unstructured":"Cree BA, Hartung HP. Steering through complexity: management approaches in multiple sclerosis. Curr Opin Neurol. 2016;29(3):263\u201371.","journal-title":"Curr Opin Neurol"},{"key":"532_CR15","doi-asserted-by":"publisher","first-page":"1063904","DOI":"10.3389\/fneur.2022.1063904","volume":"13","author":"DT Ubbink","year":"2022","unstructured":"Ubbink DT, Damman OC, de Jong BA. Shared decision-making in patients with multiple sclerosis. Front Neurol. 2022;13:1063904.","journal-title":"Front Neurol"},{"key":"532_CR16","unstructured":"FDA. OCREVUS Prescribing Information. 2017. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 18 Nov 2022."},{"issue":"3","key":"532_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2016","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2016;376(3):209\u201320.","journal-title":"N Engl J Med"},{"issue":"14","key":"532_CR18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1177\/1352458518800800","volume":"24","author":"EA Mills","year":"2018","unstructured":"Mills EA, Begay JA, Fisher C, Mao-Draayer Y. Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS. Mult Scler. 2018;24(14):1795\u2013807.","journal-title":"Mult Scler"},{"key":"532_CR19","unstructured":"EMA. OCREVUS Summary of Product Characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. Accessed 23 Nov 2022."},{"issue":"12","key":"532_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2020;19(12):998\u20131009.","journal-title":"Lancet Neurol"},{"key":"532_CR21","unstructured":"FDA. NOVANTRONE\u00aemitoXANTRONE for injection concentrate. 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019297s030s031lbl.pdf. Accessed 9 Dec 2022."},{"issue":"9350","key":"532_CR22","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"H-P Hartung","year":"2002","unstructured":"Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018\u201325.","journal-title":"Lancet"},{"issue":"5","key":"532_CR23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1212\/01.wnl.0000174439.70369.7a","volume":"65","author":"H Krapf","year":"2005","unstructured":"Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung H-P. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology. 2005;65(5):690\u20135.","journal-title":"Neurology"},{"key":"532_CR24","unstructured":"FDA. Mitoxantrone Hydrochloride (marketed as Novantrone and generics) - Healthcare Professional Sheet text version. 2008. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/mitoxantrone-hydrochloride-marketed-novantrone-and-generics-healthcare-professional-sheet-text. Accessed 9 Dec 2022."},{"issue":"Suppl 2","key":"532_CR25","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1007\/s10072-009-0142-7","volume":"30","author":"V Martinelli","year":"2009","unstructured":"Martinelli V, Radaelli M, Straffi L, Rodegher M, Comi G. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci. 2009;30(Suppl 2):S167\u201370.","journal-title":"Neurol Sci"},{"issue":"10127","key":"532_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase\u00a03 study. Lancet. 2018;391(10127):1263\u201373.","journal-title":"Lancet"},{"key":"532_CR27","unstructured":"EMA. Mayzent. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent. Accessed 19 Dec 2022."},{"key":"532_CR28","unstructured":"FDA. FDA approves new oral drug to treat multiple sclerosis. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-oral-drug-treat-multiple-sclerosis. Accessed 9 Dec 2022."},{"issue":"9","key":"532_CR29","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1007\/s00415-022-11166-z","volume":"269","author":"R Gold","year":"2022","unstructured":"Gold R, Piani-Meier D, Kappos L, et al. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase\u00a03 EXPAND study. J Neurol. 2022;269(9):5093\u2013104.","journal-title":"J Neurol"},{"issue":"1","key":"532_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","volume":"15","author":"M Tintore","year":"2019","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019;15(1):53\u20138.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"532_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026421","volume":"9","author":"A Bogosian","year":"2019","unstructured":"Bogosian A, Morgan M, Moss-Morris R. Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study. BMJ Open. 2019;9(3): e026421.","journal-title":"BMJ Open"},{"issue":"7","key":"532_CR32","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","volume":"37","author":"J Bowen","year":"2020","unstructured":"Bowen J, Mehta R, Pelletier C, et al. Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy. Adv Ther. 2020;37(7):3163\u201377.","journal-title":"Adv Ther"},{"issue":"2","key":"532_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/acn3.51282","volume":"8","author":"E Fernandez-Diaz","year":"2021","unstructured":"Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021;8(2):385\u201394.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"532_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/ene.14589","volume":"28","author":"V Lepore","year":"2021","unstructured":"Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. Eur J Neurol. 2021;28(2):567\u201378.","journal-title":"Eur J Neurol"},{"issue":"5","key":"532_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/1352458520926869","volume":"27","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Spelman T, Butzkueven H, et al. Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Mult Scler. 2021;27(5):719\u201328.","journal-title":"Mult Scler"},{"issue":"6","key":"532_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/03007995.2021.1904860","volume":"37","author":"J Chataway","year":"2021","unstructured":"Chataway J, Murphy N, Khurana V, Schofield H, Findlay J, Adlard N. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. Curr Med Res Opin. 2021;37(6):995\u20131004.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"532_CR37","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"532_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40120-020-00224-1","volume":"10","author":"EE Neuberger","year":"2021","unstructured":"Neuberger EE, Abbass IM, Jones E, Engmann NJ. Work productivity outcomes associated with ocrelizumab compared with other disease-modifying therapies for multiple sclerosis. Neurol Ther. 2021;10(1):183\u201396.","journal-title":"Neurol Ther"},{"issue":"15","key":"532_CR39","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40265-018-0984-5","volume":"78","author":"LE Baldassari","year":"2018","unstructured":"Baldassari LE, Fox RJ. Therapeutic advances and challenges in the treatment of progressive multiple sclerosis. Drugs. 2018;78(15):1549\u201366.","journal-title":"Drugs"},{"issue":"12","key":"532_CR40","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","volume":"18","author":"S Faissner","year":"2019","unstructured":"Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Rev Drug Discov. 2019;18(12):905\u201322.","journal-title":"Nature Rev Drug Discov"},{"issue":"12","key":"532_CR41","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-90.e2.","journal-title":"Am J Med"},{"key":"532_CR42","first-page":"205521731666540","volume":"2","author":"BI Glanz","year":"2016","unstructured":"Glanz BI, Greeke E, LaRussa A, et al. Risk attitudes and risk perceptions in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016;2:2055217316665406.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11","key":"532_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041249","volume":"10","author":"I Gil-Gonz\u00e1lez","year":"2020","unstructured":"Gil-Gonz\u00e1lez I, Mart\u00edn-Rodr\u00edguez A, Conrad R, P\u00e9rez-San-Gregorio M. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020;10(11): e041249.","journal-title":"BMJ Open"},{"issue":"3","key":"532_CR44","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","volume":"76","author":"Y Naegelin","year":"2019","unstructured":"Naegelin Y, Naegelin P, von Felten S, et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurol. 2019;76(3):274\u201381.","journal-title":"JAMA Neurol"},{"issue":"3","key":"532_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001148","volume":"9","author":"P Vermersch","year":"2022","unstructured":"Vermersch P, Brieva-Ruiz L, Fox RJ, et al. Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase\u00a03, clinical trial. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1148.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Suppl 1","key":"532_CR46","first-page":"S43","volume":"37","author":"CW Hollen","year":"2020","unstructured":"Hollen CW, Paz Sold\u00e1n MM, Rinker JR 2nd, Spain RI. The future of progressive multiple sclerosis therapies. Fed Pract. 2020;37(Suppl 1):S43\u20139.","journal-title":"Fed Pract"},{"issue":"1","key":"532_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7224\/1537-2073.2013-006","volume":"16","author":"ML Filipi","year":"2014","unstructured":"Filipi ML, Beavin J, Brillante RT, et al. Nurses\u2019 perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. Int J MS Care. 2014;16(1):55\u201360.","journal-title":"Int J MS Care"},{"issue":"4","key":"532_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.7224\/1537-2073.2015-042","volume":"18","author":"J Halper","year":"2016","unstructured":"Halper J, Centonze D, Newsome SD, et al. Management strategies for flu-like symptoms and injection-site reactions associated with peginterferon beta-1a: obtaining recommendations using the Delphi Technique. Int J MS Care. 2016;18(4):211\u20138.","journal-title":"Int J MS Care"},{"issue":"12","key":"532_CR49","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2165\/00023210-200216120-00004","volume":"16","author":"D Simpson","year":"2002","unstructured":"Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825\u201350.","journal-title":"CNS Drugs"},{"issue":"1s","key":"532_CR50","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.chest.2020.03.012","volume":"158","author":"X Wang","year":"2020","unstructured":"Wang X, Cheng Z. Cross-sectional studies: strengths, weaknesses, and recommendations. Chest. 2020;158(1s):S65-71.","journal-title":"Chest"},{"issue":"4","key":"532_CR51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1756285613488434","volume":"6","author":"HF Harbo","year":"2013","unstructured":"Harbo HF, Gold R, Tintor\u00e9 M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):237\u201348.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"532_CR52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/1352458519887328","volume":"26","author":"L Amezcua","year":"2020","unstructured":"Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler J. 2020;26(5):561\u20137.","journal-title":"Mult Scler J"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T01:13:38Z","timestamp":1699319618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00532-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Crystal Watson, Kiren Kresa-Reahl, Arie Barlev, and Sasha Bogdanovich are employees and shareholders of Atara Biotherapeutics. Dhanalakshmi Thirumalai was an employee and shareholder of Atara Biotherapeutics at the time of the study. Eddie Jones is an employee of Adelphi Real World.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data provider (Adelphi Real World, Bollington, UK) and Western Institutional Review Board (Puyallup, WA, USA) confirmed that ethics committee approval was not required for this analysis, as it was based on previous studies, data were de-identified, and no new studies of human or animal subjects were performed by any of the authors. This research is compliant with the US Health Insurance Portability and Accountability Act 1996. This study was performed in accordance with Helsinki Declaration of 1964, and its later amendments. All subjects provided informed consent. Atara Biotherapeutics subscribed to the Adelphi MS DSP; this subscription granted access to analyze and publish from the dataset.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}